OncoCyte Corp
NASDAQ:OCX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
OncoCyte Corp
NASDAQ:OCX
|
US |
|
C
|
CYND Co Ltd
TSE:4256
|
JP |
|
I
|
Intorio Corp
OTC:ITOR
|
US |
|
B
|
Bioventus Inc
NASDAQ:BVS
|
US |
|
JW Pharmaceutical Corp
KRX:001060
|
KR |
|
R
|
Retal Urban Development Company SJSC
SAU:4322
|
SA |
|
Camden National Corp
NASDAQ:CAC
|
US |
|
NC Holdings Co Ltd
TSE:6236
|
JP |
|
C
|
Carrefour SA
F:CAR
|
FR |
|
Golden Mile Resources Ltd
ASX:G88
|
AU |
|
Takebishi Corp
TSE:7510
|
JP |
|
S
|
Selena FM SA
WSE:SEL
|
PL |
|
Nitto Fuji Flour Milling Co Ltd
TSE:2003
|
JP |
|
G
|
GiXo Ltd
TSE:9219
|
JP |
|
Simona AG
F:SIM0
|
DE |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
|
P
|
Pureun Mutual Savings Bank
KOSDAQ:007330
|
KR |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is OCX's stock price target?
Not Available
OCX does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for OncoCyte Corp?
Projected CAGR
92%
The compound annual growth rate for Revenue over the next 3 years is 92%.